Clinical trials: ERCP
Post-ERCP Acute Pancreatitis
Rectal Indomethacin vs Intravenous Ketorolac
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential procedure that can be complicated by post-ERCP pancreatitis (PEP). Indomethacin and ketorolac are two medications used to prevent PEP.
- Trial name
- NCT05664074
- Testing
- Rectal indomethacin, IV ketorolac
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- David Vitale MD
Post-ERCP Acute Pancreatitis
Study of Forceps Cannulation During ERCP
A difficult cannulation has been identified as one of the high risk factors for developing post-ERCP pancreatitis (PEP). The accessibility and morphology of the papilla influence the level of cannulation difficulty.
- Trial name
- SOCCER (NCT05336630)
- Testing
- Forceps
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Post-ERCP Pancreatitis
Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Background: Pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP), accounting for substantial morbidity, occasional mortality, and increased health care expenditures.
- Trial name
- SVI (NCT02476279)
- Testing
- Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement, Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
- Where
- 20 sites in United States, Canada
- Volunteers
- 1,950 people
- Sponsor
- Medical University of South Carolina
Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP)
Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures
The purpose of this study is to compare meperidine/midazolam with diphenhydramine, meperidine/midazolam with promethazine, and meperidine/midazolam with placebo as sedation methods.
- Trial name
- NCT00937924
- Testing
- Meperidine, Midazolam, Diphenhydramine, Promethazine
- Where
- United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Post-ERCP Acute Pancreatitis
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common, serious complication of ERCP. More than 500,000 ERCP procedures are performed from which 25,000 cases of PEP occur in the U.S.A.
- Trial name
- NCT03098082
- Testing
- Actim Pancreatitis
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- Indiana University
Post-ERCP Acute Pancreatitis
IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis
Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced endoscopic technique utilized to diagnose and treat pathologic conditions involving the ducts draining the liver and pancreas.
- Trial name
- NCT02241512
- Testing
- Ibuprofen
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Texas Southwestern Medical Center
Post-ERCP Pancreatitis
Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
It is now established that indomethacin, a non-steroidal anti-inflammatory drug, at a dose of 100 mg, is effective in reducing the frequency and severity of pancreatitis (inflammation of the pancreas) after endoscopic retrograde…
- Trial name
- NCT01912716
- Testing
- high dose indomethacin, standard dose indomethacin
- Where
- 6 sites in United States
- Volunteers
- 1,037 people
- Sponsor
- Indiana University
Post-ERCP Acute Pancreatitis
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP pancreatitis is a well-known and sometimes life-threatening complication of ERCP. Both LR and rectal indomethacin have shown benefit in preventing post-ERCP pancreatitis.
- Trial name
- IND+LRPEP (NCT02641561)
- Testing
- Indomethacin, Lactated Ringer's Solution, Normal Saline
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- The Cooper Health System
Post-ERCP Acute Pancreatitis
Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
This research is being done to see if using a combination of rectal indomethacin and epinephrine spray during endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
- Trial name
- INDIEH (NCT02116309)
- Testing
- Rectal Indomethacin, Epinephrine
- Where
- 4 sites in United States, India
- Volunteers
- 948 people
- Sponsor
- Johns Hopkins University
Post-ERCP Acute Pancreatitis
Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
- Trial name
- NCT01774604
- Testing
- Indomethacin
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Post-ERCP Acute Pancreatitis
Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- Indomethacin (NCT02002650)
- Testing
- Pre-ERCP rectal Indomethacin, Post-operational Rectal Indomethacin
- Where
- 6 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Pancreatitis
Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients
Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of disorders of the pancreas and bile duct.
- Trial name
- NCT00820612
- Testing
- Indomethacin
- Where
- 4 sites in United States
- Volunteers
- 602 people
- Sponsor
- University of Michigan
ERCP, Pancreatic Diseases
Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)
The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.
- Conditions
- ERCP, Pancreatic Diseases, Bile Duct Diseases
- Trial name
- NCT00731198
- Testing
- Drotaverine hydrochloride, Hyoscine-N-butylbromide
- Where
- 4 sites in China
- Volunteers
- 650 people
- Sponsor
- Changhai Hospital